Hope Rugo, MD, FASCO and Aditya Bardia MD, MPH, FASCOexplore strategies for managing antibody drug conjugate (ADC)-related toxicities in breast cancer, covering current ADCs, real-world management practices, and future directions, in this OncLive Insights video series.
EP. 1: Overview of Current ADCs in Breast Cancer
August 21st 2024Medical experts review the currently available antibody-drug conjugates for breast cancer, including Sacituzumab govitecan (Trop-2 directed ADC), Kadcyla (ado-trastuzumab emtansine, T-DM1, HER2-directed ADC), and Enhertu (fam-trastuzumab deruxtecan-nxki, T-DXd, HER2-directed ADC).
EP. 2: ADCs in Breast Cancer: Mechanism of Action, and Components
August 21st 2024Medical experts discuss the distinct mechanisms and components of different antibody-drug conjugates (ADCs), including the drug, antibody, and linker, and how these components contribute to the mechanisms of ADC-related toxicities.
EP. 4: Expert Perspectives on the Management of SG-Related Neutropenia
August 28th 2024This discussion focuses on strategies to manage neutropenia associated with SG, including the use of prophylactic growth factors and timing of their administration, comparing management approaches between clinicians.
EP. 5: Navigating SG-related Diarrhea
September 4th 2024Panelists discuss how to manage sacituzumab govitecan therapy, including absolute neutrophil count cutoffs for dose adjustments, handling febrile neutropenia, comparing diarrhea rates to clinical trials, identifying risk factors, and strategies for managing SG-related diarrhea.
EP. 6: Expert Insights: SG Adverse Events Management including Alopecia & Nausea
September 4th 2024Panelists discuss how to manage side effects of sacituzumab govitecan (SG), including counseling on alopecia, proactive management strategies, routine antiemetic premedications, and adjustments for chemotherapy-induced nausea and vomiting, as well as recommended breakthrough antinausea medications for home use.
Ipilimumab Plus Nivolumab Increases 12-Month OS Rate vs SOC in nccRCC
Benmelstobart Plus Anlotinib Demonstrates Efficacy in Frontline Advanced RCC
Neoadjuvant Chemotherapy Could Enhance Organ Preservation in Nasal and Paranasal Sinus Squamous Cell Carcinoma
Dr Andre on the Efficacy of Nivolumab/Ipilimumab in MSI-H/dMMR mCRC Subgroups
2 Commerce Drive
Cranbury, NJ 08512